Assembly Biosciences, INC 8-K filings

Assembly Biosciences reported Q2 2026 results, highlighting a $115 million financing, expansion of ABI-6250 into new indications, and progress on the GS-1179 HSV program, with cash runway projected into 2029.

Assembly Biosciences stockholders approved key equity incentive plan amendments and re-elected the board of directors.

Assembly Biosciences announced the pricing of an underwritten offering of common stock and pre-funded warrants, raising approximately $100 million before expenses.

Assembly Biosciences is expanding the clinical development of its oral entry inhibitor, ABI-6250, into PBC and PSC liver diseases.

Assembly Biosciences approved a 2026 cash bonus plan and raised CEO Jason Okazaki’s target bonus to 65% of base salary.

Assembly Biosciences reported strong year-end 2025 financial results, highlighted by a successful licensing deal with Gilead for its herpes program and a significant increase in cash reserves.

Assembly Biosciences reports positive interim Phase 1b results for ABI-1179 and ABI-5366, showing significant reductions in viral shedding and genital lesions for recurrent genital herpes.

Assembly Biosciences announced positive Phase 1b interim results for its genital herpes and HDV candidates, completed a $175 million equity financing, and reported third-quarter 2025 financial results.

Assembly Biosciences completed a $167 million equity financing through an underwritten offering and a concurrent private placement with Gilead Sciences, Inc.

Assembly Biosciences announced positive interim Phase 1b results for ABI-5366, an investigational long-acting herpes simplex virus inhibitor, showing significant reductions in viral shedding and genital lesions.

Assembly Biosciences reported its second quarter 2025 financial results and provided positive clinical updates for its HBV and HSV programs, alongside interim data for its HDV candidate.

Assembly Biosciences announced positive topline results from its Phase 1b clinical trial of ABI-4334 for chronic hepatitis B, which triggers an opt-in point for its collaboration with Gilead Sciences.

Assembly Biosciences, Inc. announced stockholder approval of amendments to its stock incentive and employee stock purchase plans, increasing shares available for issuance, and the appointment of Jeanette M. Bjorkquist as Principal Financial Officer.

Assembly Biosciences announced its Q1 2025 financial results, highlighting ongoing clinical studies and upcoming data releases for its antiviral candidates.

Assembly Biosciences announces its year-end 2024 financial results, highlighting progress in its antiviral pipeline and anticipated clinical data readouts in 2025.

Assembly Biosciences reports positive interim Phase 1a results for ABI-1179, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor, showing it was well-tolerated with a favorable pharmacokinetic profile, supporting once-weekly oral administration.

Assembly Biosciences has extended its office and laboratory sublease in South San Francisco through September 2029, with an option to expand into additional space.

Assembly Biosciences reported encouraging interim results from a Phase 1b trial of its hepatitis B drug candidate, ABI-4334, showing strong antiviral activity and a favorable safety profile.

Assembly Biosciences and Gilead Sciences have amended their collaboration agreement, resulting in a $10 million payment to Assembly and a restructured opt-in fee for ABI-6250, alongside an additional equity purchase by Gilead.

Assembly Biosciences has amended its bylaws, introducing stricter requirements for stockholder nominations and proposals at annual meetings.

Assembly Biosciences has entered into an agreement with Jefferies LLC to sell up to $75 million of its common stock through an at-the-market offering program.

Assembly Biosciences announced positive interim Phase 1a data for their herpes treatment candidate, ABI-5366, and provided updates on their clinical pipeline and financial status for Q3 2024.

Assembly Biosciences reports positive interim Phase 1a results for ABI-5366, a long-acting herpes simplex virus inhibitor, showing a favorable safety profile and a half-life supporting once-weekly or once-monthly dosing.

Assembly Biosciences announced the initiation of dosing in two clinical trials, positive financial results, and provided updates on their antiviral pipeline.

Assembly Biosciences has raised approximately $12.6 million through separate equity financings with Armistice Capital and Gilead Sciences to support its antiviral drug development programs.

Assembly Biosciences' stockholders approved amendments to the 2018 Stock Incentive Plan and the 2018 Employee Stock Purchase Plan at the annual meeting on May 29, 2024.

Assembly Biosciences reported its Q1 2024 financial results, highlighting progress in clinical trials for its antiviral therapies and a decrease in net loss compared to the same period last year.

Assembly Biosciences announced its 2023 year-end financial results, highlighted by a strengthened cash position and advancements in its antiviral pipeline, including accelerated timelines for key clinical programs.

Assembly Biosciences has appointed a new board member from Gilead Sciences and approved a new corporate bonus plan effective January 1, 2024.

Assembly Biosciences has completed a 1-for-12 reverse stock split of its common stock, effective February 9, 2024, to meet Nasdaq's minimum bid price requirement.